JSON
Essand M, Leja J, Giandomenico V, Oberg KE
Horm. Metab. Res. 43 (12) 877-883 [2011-11-00; online 2011-05-30]
Oncolytic viruses are emerging as anticancer agents, and they have also shown great promise for use against neuroendocrine tumors. Many viruses have a natural tropism for replication in tumor cells. Others can be genetically engineered to selectively kill tumor cells. Viruses have some advantages as therapeutic agents over current cytotoxic drugs and small molecules. They replicate in tumor cells and thereby increase in number over time leading to increased dosage. They are immunogenic and can alter the immunosuppressive tumor microenvironment and activate immune effector cells. They have also been shown to be able to kill drug-resistant cancer stem cells. This article reviews the recent literature on oncolytic viruses used so far for neuroendocrine tumors and indicates important issues to focus on in the future.
PubMed 21626470
DOI 10.1055/s-0031-1277225
Crossref 10.1055/s-0031-1277225